{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:56:47Z","timestamp":1784001407200,"version":"3.55.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003751","name":"Ministerio de Sanidad, Servicios Sociales e Igualdad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["BIO-0139"],"award-info":[{"award-number":["BIO-0139"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PI-0038\/2019"],"award-info":[{"award-number":["PI-0038\/2019"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PI-0094-2020"],"award-info":[{"award-number":["PI-0094-2020"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PI-0152-2019"],"award-info":[{"award-number":["PI-0152-2019"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["RH-0084-2020"],"award-info":[{"award-number":["RH-0084-2020"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012514","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012514","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2019-105564RB-I00\/FPU16-05059"],"award-info":[{"award-number":["PID2019-105564RB-I00\/FPU16-05059"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["ISCIII-AES-2019\/002525"],"award-info":[{"award-number":["ISCIII-AES-2019\/002525"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["PI20\/01301"],"award-info":[{"award-number":["PI20\/01301"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Government of Spain Ministry of Science, Innovation and Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008679","name":"Universidad de C\u00f3rdoba","doi-asserted-by":"publisher","award":["27416"],"award-info":[{"award-number":["27416"]}],"id":[{"id":"10.13039\/501100008679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.coph.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T08:55:31Z","timestamp":1627030531000},"page":"17-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2668-8205","authenticated-orcid":false,"given":"Antonio J.","family":"Le\u00f3n-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4391-3726","authenticated-orcid":false,"given":"Juan M.","family":"Jim\u00e9nez-Vacas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2069-4823","authenticated-orcid":false,"given":"Antonio C.","family":"Fuentes-Fayos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1204-0371","authenticated-orcid":false,"given":"Andre","family":"Sarmento-Cabral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aura D.","family":"Herrera-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel D.","family":"Gahete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal M.","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2021.06.002_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","article-title":"The global epidemic of the metabolic syndrome","volume":"20","author":"Saklayen","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.coph.2021.06.002_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000443743","article-title":"Association between metabolic syndrome and cancer","volume":"68","author":"Uzunlulu","year":"2016","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.coph.2021.06.002_bib3","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/jcmm.13994","article-title":"Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer","volume":"23","author":"Gomez-Gomez","year":"2019","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.coph.2021.06.002_bib4","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bju.12843","article-title":"Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study","volume":"115","author":"Sourbeer","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.coph.2021.06.002_bib5","doi-asserted-by":"crossref","first-page":"554078","DOI":"10.3389\/fendo.2021.554078","article-title":"Endocrinology of the aging prostate: current concepts","volume":"12","author":"Cannarella","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.coph.2021.06.002_bib6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.sxmr.2018.10.006","article-title":"Testosterone and benign prostatic hyperplasia","volume":"7","author":"Rastrelli","year":"2019","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.coph.2021.06.002_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1530\/JOE-11-0289","article-title":"Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit","volume":"212","author":"Vignozzi","year":"2012","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.coph.2021.06.002_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pros.22723","article-title":"Opposite effects of tamoxifen on metabolic syndrome-induced bladder and prostate alterations: a role for GPR30\/GPER?","volume":"74","author":"Comeglio","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.coph.2021.06.002_sref9","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3389\/fonc.2020.00942","article-title":"The role of aberrant metabolism in cancer: insights into the interplay between cell metabolic reprogramming, metabolic syndrome, and cancer","volume":"10","author":"Yu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.coph.2021.06.002_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2021.06.002_bib11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2017.06.007","article-title":"Repurposing drugs in oncology: next steps","volume":"3","author":"Verbaanderd","year":"2017","journal-title":"Trends Canc"},{"key":"10.1016\/j.coph.2021.06.002_bib12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc21-Sint","article-title":"Introduction: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coph.2021.06.002_sref13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tem.2020.05.004","article-title":"Rethinking the relationship between insulin and cancer","volume":"31","author":"Vigneri","year":"2020","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.coph.2021.06.002_bib14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/pros.23517","article-title":"Stimulating effect of palmitate and insulin on cell migration and proliferation in PNT1A and PC3 prostate cells: counteracting role of metformin","volume":"78","author":"Landim","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.coph.2021.06.002_bib15","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/jcmm.13109","article-title":"Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and IGF1","volume":"21","author":"L-L\u00f3pez","year":"2017","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.coph.2021.06.002_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113615","article-title":"Insulin receptor isoforms in cancer","volume":"19","author":"Vella","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2021.06.002_bib17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/pros.22623","article-title":"Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation","volume":"73","author":"Vignozzi","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.coph.2021.06.002_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102984","article-title":"Inflammation as a driver of prostate cancer metastasis and therapeutic resistance","volume":"12","author":"Archer","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.coph.2021.06.002_bib19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrurol.2014.143","article-title":"Prostate cancer: intriguing data on inflammation and prostate cancer","volume":"11","author":"Vignozzi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.coph.2021.06.002_bib20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13058-015-0611-2","article-title":"Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in\u00a0vitro, animal and human evidence","volume":"17","author":"Bronsveld","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.coph.2021.06.002_sref21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fendo.2020.00058","article-title":"Metabolic health, insulin, and breast cancer: why oncologists should care about insulin","volume":"11","author":"Yee","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.coph.2021.06.002_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40264-019-00892-5","article-title":"The use of long-acting insulin analogs and the risk of colorectal cancer among patients with type 2 diabetes: a population-based cohort study","volume":"43","author":"Pradhan","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.coph.2021.06.002_bib23","doi-asserted-by":"crossref","first-page":"81462","DOI":"10.18632\/oncotarget.20399","article-title":"Breast cancer is associated to impaired glucose\/insulin homeostasis in premenopausal obese\/overweight patients","volume":"8","author":"Luque","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.coph.2021.06.002_bib24","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1172\/JCI114868","article-title":"Elevated insulin receptor content in human breast cancer","volume":"86","author":"Papa","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.coph.2021.06.002_bib25","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.numecd.2018.02.010","article-title":"Long-acting insulin analogs and cancer","volume":"28","author":"Sciacca","year":"2018","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.coph.2021.06.002_bib26","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/jcp.24635","article-title":"Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression","volume":"229","author":"Sciacca","year":"2014","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.coph.2021.06.002_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/BF00400425","article-title":"Insulin analogues and carcinoma of the breast","volume":"39","author":"Ebeling","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2021.06.002_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/13813451003631439","article-title":"Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells","volume":"116","author":"Mayer","year":"2010","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.coph.2021.06.002_bib29","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00125-009-1444-2","article-title":"Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden","volume":"52","author":"Jonasson","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2021.06.002_bib30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2337\/dc15-1816","article-title":"Effect of long-acting insulin analogs on the risk of cancer: a systematic review of observational studies","volume":"39","author":"Wu","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coph.2021.06.002_bib31","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2337\/dc13-1468","article-title":"The association of basal insulin glargine and\/or n-3 fatty acids with incident cancers in patients with dysglycemia","volume":"37","author":"Bordeleau","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coph.2021.06.002_bib32","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.2337\/dc11-0699","article-title":"Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients","volume":"34","author":"Morden","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coph.2021.06.002_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092559","article-title":"Insulin resistance and endometrial cancer: emerging role for microRNA","volume":"12","author":"Sidorkiewicz","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.coph.2021.06.002_bib34","doi-asserted-by":"crossref","first-page":"920618","DOI":"10.1155\/2015\/920618","article-title":"The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms","volume":"2015","author":"Joung","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.coph.2021.06.002_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fendo.2019.00481","article-title":"Insulin enhances migration and invasion in prostate cancer cells by up-regulation of FOXC2","volume":"10","author":"Sarkar","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.coph.2021.06.002_bib36","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00125-017-4312-5","article-title":"Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study","volume":"60","author":"But","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2021.06.002_bib37","article-title":"Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies","volume":"8","author":"Chen","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.coph.2021.06.002_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13300-018-0557-3","article-title":"Association between metformin and sulfonylurea monotherapies and cancer incidence: a real-world cohort study in Shanghai, China","volume":"10","author":"Ye","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.coph.2021.06.002_bib39","doi-asserted-by":"crossref","first-page":"172598","DOI":"10.1016\/j.ejphar.2019.172598","article-title":"Sulfonylurea derivatives and cancer, friend or foe?","volume":"861","author":"Hendriks","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2021.06.002_bib40","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: from mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metabol"},{"key":"10.1016\/j.coph.2021.06.002_bib41","first-page":"443","article-title":"Document on a comprehensive approach to type 2 diabetes mellitus","volume":"66","author":"Reyes-Garcia","year":"2019","journal-title":"Endocrinol Diabetes Nutr"},{"key":"10.1016\/j.coph.2021.06.002_bib42","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2021.06.002_bib43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","article-title":"Cellular and molecular mechanisms of metformin action","volume":"42","author":"LaMoia","year":"2021","journal-title":"Endocr Rev"},{"key":"10.1016\/j.coph.2021.06.002_bib44","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1159\/000493448","article-title":"The pituitary gland is a novel major site of action of metformin in non-human primates: a potential path to expand and integrate its metabolic actions","volume":"49","author":"Vazquez-Borrego","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.coph.2021.06.002_sref45","doi-asserted-by":"crossref","first-page":"117717","DOI":"10.1016\/j.lfs.2020.117717","article-title":"Anticancer mechanisms of metformin: a review of the current evidence","volume":"254","author":"Zhao","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.coph.2021.06.002_bib46","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fendo.2020.00191","article-title":"Metformin and its benefits for various diseases","volume":"11","author":"Lv","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.coph.2021.06.002_bib47","doi-asserted-by":"crossref","first-page":"74673","DOI":"10.18632\/oncotarget.20341","article-title":"Metformin inhibits esophageal squamous cell carcinoma-induced angiogenesis by suppressing JAK\/STAT3 signaling pathway","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.coph.2021.06.002_bib48","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/1440-1681.13073","article-title":"NF-kappaB as the mediator of metformin's effect on ageing and ageing-related diseases","volume":"46","author":"Kanigur Sultuybek","year":"2019","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.coph.2021.06.002_bib49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/ncomms1859","article-title":"Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC","volume":"3","author":"Blandino","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2021.06.002_bib50","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/onc.2017.367","article-title":"Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism","volume":"37","author":"Cuyas","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.coph.2021.06.002_bib51","doi-asserted-by":"crossref","first-page":"39939","DOI":"10.18632\/oncotarget.17829","article-title":"Metformin induces protein acetylation in cancer cells","volume":"8","author":"Vancura","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.coph.2021.06.002_bib52","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1210\/clinem\/dgaa580","article-title":"Influence of obesity in the miRNome: miR-4454, a key regulator of insulin response via splicing modulation in prostate","volume":"106","author":"Herrero-Aguayo","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.06.002_sref53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1210\/jc.2018-01455","article-title":"Type 2 diabetes in neuroendocrine tumors: are biguanides and statins part of the solution?","volume":"104","author":"Herrera-Martinez","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.06.002_sref54","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1210\/clinem\/dgaa877","article-title":"Clinical, cellular and molecular evidence of the additive antitumor effects of biguanides and statins in prostate cancer","volume":"106","author":"Jimenez-Vacas","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.06.002_sref55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092482","article-title":"Counteracting chemoresistance with metformin in breast cancers: targeting cancer stem cells","volume":"12","author":"Samuel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.coph.2021.06.002_bib56","first-page":"95","article-title":"Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer","volume":"13","author":"Wen","year":"2020","journal-title":"J\u00a0Ovarian Res"},{"key":"10.1016\/j.coph.2021.06.002_bib57","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1530\/JME-19-0083","article-title":"The role of an anti-diabetic drug metformin in the treatment of endocrine tumors","volume":"63","author":"Thakur","year":"2019","journal-title":"J\u00a0Mol Endocrinol"},{"key":"10.1016\/j.coph.2021.06.002_bib58","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/1541-7786.MCR-16-0493","article-title":"Metformin reduces prostate tumor growth, in a diet-dependent manner, by modulating multiple signaling pathways","volume":"15","author":"Sarmento-Cabral","year":"2017","journal-title":"Mol Canc Res"},{"key":"10.1016\/j.coph.2021.06.002_bib59","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1210\/jc.2019-00056","article-title":"Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and -independent mechanisms","volume":"104","author":"Vazquez-Borrego","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.06.002_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228540","article-title":"Current status and application of metformin for prostate cancer: a comprehensive review","volume":"21","author":"Ahn","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2021.06.002_bib61","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21681805.2016.1271353","article-title":"Antidiabetic drug use and prostate cancer risk in the Finnish randomized study of screening for prostate cancer","volume":"51","author":"Haring","year":"2017","journal-title":"Scand J Urol"},{"key":"10.1016\/j.coph.2021.06.002_bib62","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/CEJ.0000000000000394","article-title":"Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort","volume":"27","author":"Nguyen","year":"2018","journal-title":"Eur J Canc Prev"},{"key":"10.1016\/j.coph.2021.06.002_bib63","doi-asserted-by":"crossref","first-page":"595","DOI":"10.7314\/APJCP.2015.16.2.595","article-title":"Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Hwang","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.coph.2021.06.002_bib64","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","article-title":"Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis","volume":"27","author":"Coyle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2021.06.002_bib65","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1158\/1940-6207.CAPR-15-0141","article-title":"Metformin use and risk of prostate cancer: results from the REDUCE study","volume":"8","author":"Feng","year":"2015","journal-title":"Canc Prev Res"},{"key":"10.1016\/j.coph.2021.06.002_bib66","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1186\/s12885-017-3458-3","article-title":"Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer","volume":"17","author":"Crawley","year":"2017","journal-title":"BMC Canc"},{"key":"10.1016\/j.coph.2021.06.002_bib67","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.eururo.2016.07.015","article-title":"Repurposing metformin as therapy for prostate cancer within the STAMPEDE trial platform","volume":"70","author":"Gillessen","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.coph.2021.06.002_bib68","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41391-018-0085-2","article-title":"The anticancer potential of metformin on prostate cancer","volume":"22","author":"Zaidi","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.coph.2021.06.002_bib69","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling","year":"2007","journal-title":"Canc Res"},{"key":"10.1016\/j.coph.2021.06.002_bib70","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","article-title":"The antidiabetic drug metformin exerts an antitumoral effect in\u00a0vitro and in\u00a0vivo through a decrease of cyclin D1 level","volume":"27","author":"Ben Sahra","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.coph.2021.06.002_sref71","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.breast.2019.08.003","article-title":"A\u00a0phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy","volume":"48","author":"Pimentel","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.coph.2021.06.002_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/biom9120846","article-title":"Metformin: the answer to cancer in a flower? Current knowledge and future prospects of metformin as an anti-cancer agent in breast cancer","volume":"9","author":"Samuel","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.coph.2021.06.002_bib73","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.annonc.2020.12.008","article-title":"A\u00a0prospective study of type 2 diabetes, metformin use, and risk of breast cancer","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2021.06.002_bib74","doi-asserted-by":"crossref","first-page":"127003","DOI":"10.1289\/EHP1923","article-title":"The sister study cohort: baseline methods and participant characteristics","volume":"125","author":"Sandler","year":"2017","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.coph.2021.06.002_bib75","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/jnci\/djaa082","article-title":"The effect of metformin vs placebo on sex hormones in CCTG MA.32","volume":"113","author":"Pimentel","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.coph.2021.06.002_bib76","first-page":"7180923","article-title":"Metformin: a possible option in cancer chemotherapy","volume":"2020","author":"Ugwueze","year":"2020","journal-title":"Anal Cell Pathol (Amst)"},{"key":"10.1016\/j.coph.2021.06.002_bib77","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5468\/ogs.2020.63.3.215","article-title":"Associations between metabolic syndrome and gynecologic cancer","volume":"63","author":"Lee","year":"2020","journal-title":"Obstet Gynecol Sci"},{"key":"10.1016\/j.coph.2021.06.002_bib78","first-page":"1","article-title":"Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome","author":"Raperport","year":"2021","journal-title":"Expet Rev Endocrinol Metabol"},{"key":"10.1016\/j.coph.2021.06.002_bib79","article-title":"Effect of metformin use on the risk and prognosis of ovarian cancer: an updated systematic review and meta-analysis","author":"Lu","year":"2019","journal-title":"Panminerva Med"},{"key":"10.1016\/j.coph.2021.06.002_bib80","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2174\/1381612825666190716113126","article-title":"No effect of metformin on ovarian cancer survival: a systematic review and meta-analysis of cohort studies","volume":"25","author":"Wang","year":"2019","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.coph.2021.06.002_bib81","article-title":"Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer","volume":"5","author":"Brown","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.coph.2021.06.002_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248103","article-title":"Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line","volume":"16","author":"Lange","year":"2021","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.coph.2021.06.002_bib83","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/COC.0000000000000756","article-title":"Is there a role for statins and metformin in cancer therapy?","volume":"43","author":"Hassanabad","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.coph.2021.06.002_bib84","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1159\/000505923","article-title":"Statins directly regulate pituitary cell function and exert antitumor effects in pituitary tumors","volume":"110","author":"Vazquez-Borrego","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.coph.2021.06.002_bib85","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","article-title":"Pharmacological actions of statins: a critical appraisal in the management of cancer","volume":"64","author":"Gazzerro","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.coph.2021.06.002_bib86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.mce.2014.01.014","article-title":"Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit","volume":"384","author":"Vignozzi","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.coph.2021.06.002_bib87","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1002\/cam4.2862","article-title":"Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer","volume":"9","author":"Tan","year":"2020","journal-title":"Canc Med"},{"key":"10.1016\/j.coph.2021.06.002_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects","volume":"16","author":"Tentolouris","year":"2019","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.coph.2021.06.002_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.145","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cancer: an overview of quantitative systematic reviews","volume":"3","author":"Pelletier","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.coph.2021.06.002_bib90","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","article-title":"SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia","volume":"7","author":"Nasiri","year":"2019","journal-title":"Canc Metabol"},{"key":"10.1016\/j.coph.2021.06.002_bib91","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00424-020-02448-4","article-title":"SGLT2 and cancer","volume":"472","author":"Wright","year":"2020","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.coph.2021.06.002_bib92","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40261-016-0389-8","article-title":"Tumour risk with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic review","volume":"36","author":"Guo","year":"2016","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.coph.2021.06.002_bib93","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12020-019-02055-z","article-title":"GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.coph.2021.06.002_bib94","article-title":"Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis","author":"Piccoli","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.06.002_sref95","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/dom.13766","article-title":"Glucose-lowering medications and the risk of cancer: a methodological review of studies based on real-world data","volume":"21","author":"Bykov","year":"2019","journal-title":"Diabetes Obes Metabol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221000722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221000722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:55:58Z","timestamp":1761461758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489221000722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":95,"alternative-id":["S1471489221000722"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2021.06.002","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}